Cyclopharm makes first sale to giant US healthcare system

Radiopharmaceutical medical imaging company Cyclopharm has received its first purchase orders from two United States Veterans Health Administration (VA) Hospitals – part of the largest integrated US Government health care system in the United States (US).

The purchase orders for an initial five-year term apply to the installation and annual charges associated with the Technegas System.

Use of Technegas, an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging, was approved for sale in the US by the US Food and Drug Administration in 2023.

The latest purchase follows the award to the company of an Interim Agreement (IA) to supply the Veterans Health Administration (VA) for the pharmaceutical and consumable components of Technegas.

Cyclopharm CEO James McBrayer said: “The purchase orders received today for the Technegas Systems, combined with the national agreement awarded last month for the patient consumables, will allow for the first installations of Technegas within the VA system during the first few weeks of 2025.

“Once installed, Technegas revenues will be generated immediately as our technology will be replacing existing nuclear medicine products.”

Technegas’ ability to provide accurate functional ventilation images is a key diagnostic aid for conditions such as chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, a condition affecting veterans impacted by toxic exposures during active service.

By improving diagnostic accuracy, Technegas will aid in the VA’s effective treatment and management of lung disease in affected veterans, according to the company.

McBrayer said:, “We are very pleased that US veterans will soon have access to our Technegas technology.

“More broadly, these initial commercial agreements will also serve as a template for the remaining 118 nuclear medicine departments located in VA hospitals.”

Browse @AuManufacturing’s coverage of Cyclopharm here.

Picture: Picture: University of Newcastle/Trial of Technegas generator